Replies to post #423051 on Amarin Corp Plc (AMRN)

[rosemountbomber]

Kiwi, if I had to propose a cynical answer to your question I would say this:

Why would anyone (other than Amarin) bother to boost their drug. These insurance companies are there to make money (by not paying for stuff) and even if you make the argument that it would save them in the long run we know that:
a) they usually don't think long term and just for the next couple of quarters, and
b) a person can jump from one insurer to the next so the insurer can not necessarily depend on having that insured for long. This is somewhat mitigated by the fact that they could lose some patients but gain others.

[MA52TA]

DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular Events) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as reducing the risk of cardiovascular (CV) events in patients irrespective of baseline LDL-C level. The REDUCE-IT analysis results relating Lp(a) concentrations with CV risk were also published online today in the Journal of the American College of Cardiology (JACC).

[Laurent Maldague]

RWE of Icosapent Ethyl at ACC 2024. 38% MACE relative risk reduction IPE vs OM3. The authors are not even Amarin affiliated, so a truly independent study.
With Bhatt's vascular progenitor study, the new science continues to build in favor of IPE. ESC 2024 will be in London this year end of August. If we get more RWE in the form of MITIGATE, that should make a big difference for the remaining EU reimbursements. Happy to hear Amarin finally PR their European patent wins and exclusivity strength.